Antistaphylococcal Activity of DX-619 Alone and in Combination with Vancomycin, Teicoplanin, and Linezolid Assessed by Time-Kill Synergy Testing | Zendy

Kim Credito | Zendy; Genrong Lin | Zendy; Peter C. Appelbaum | Zendy

Open Access

Antistaphylococcal Activity of DX-619 Alone and in Combination with Vancomycin, Teicoplanin, and Linezolid Assessed by Time-Kill Synergy Testing

Author(s) -

Kim Credito,

Genrong Lin,

Peter C. Appelbaum

Publication year - 2007

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01517-06

Subject(s) - teicoplanin , linezolid , vancomycin , staphylococcus aureus , antibiotics , microbiology and biotechnology , methicillin resistant staphylococcus aureus , medicine , antagonism , pharmacology , biology , bacteria , receptor , genetics

Time-kill synergy studies testing in vitro activity of DX-619 alone and with added vancomycin, teicoplanin, or linezolid against 101Staphylococcus aureus strains showed synergy between DX-619 and teicoplanin at 12 to 24 h in 72 strains and between DX-619 and vancomycin in 28 strains. No synergy was found with linezolid, and no antagonism was observed with any combination.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research